MYX mayne pharma group limited
Add to My Watchlist 0.20% ! $5.08

how confident are you that nuvaring will be approved?and e4 will...

  1. CarlesPuyol
    756 Posts.
    lightbulb Created with Sketch. 136
    clock Created with Sketch.
    27/08/20
    15:21
    Post #: 46871030
    how confident are you that nuvaring will be approved?

    and e4 will come sometime next year.

    to put it in context - nuvaring generic was planned for commercialisation for FY 19. can you remind me where we are now?
    MYX Price at posting: 33.5¢ Sentiment: Sell Disclosure: Held
    Likes Created with Sketch.  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

CLA Celsius Resources Commences FEED and Feasibility Study at MCB Project Site
right-arrow Created with Sketch.
NEWS Orthocell Announces First US Surgical Use of Remplir Following FDA Clearance
right-arrow Created with Sketch.
NEWS Progress in Phelan-McDermid Syndrome Program to Be Presented at PMS Global Congress
right-arrow Created with Sketch.
NEWS 30,000m Diamond Drilling Commences at Napie Gold Project
right-arrow Created with Sketch.
NEWS Strong Rock Chip Assays Include 18.4g/t Au from Waitekauri
right-arrow Created with Sketch.
NEWS Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back
right-arrow Created with Sketch.
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
$5.08 		Change
0.010(0.20%) 		Mkt cap ! $412.7M
Open High Low Value Volume
$5.13 $5.15 $5.08 $445.2K 87.01K

Buyers (Bids)

No. Vol. Price($)
1 810 $5.08
 

Sellers (Offers)

Price($) Vol. No.
$5.15 2033 2
View Market Depth
Last trade - 16.10pm 27/06/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.